Study | TAVR-PVE | SAVR-PVE | Comparison TAVR-PVE versus SAVR-PVE | ||||
Number of patients | Incidence (95% CI) | Number of patients | Incidence (95% CI) | ||||
Initial year | Overall | Initial year | Overall | ||||
Sweden*[1] 2008 to 2018 | 4336 | 1.42 (1.03-1.80) | Not available | ||||
Sweden[2] 1995 to 2012 | 16,426 | 1.17 (1.01-1.36) | 0.69 (0.64-0.75) | ||||
Denmark*[3] 2008 to 2016 | 2632 | 2.80 (1.80-2.90) | 1.2 (0.9-1.6) | 3777 | 1.8 (1.4-2.3) | 1.0 (0.8-1.1) | HR 1.12 (0.84-1.49) |
Finland¶[4] 2008 to 2017 | 2130 | 0.39 (0.21-0.71) | 0.34 (Not available) | 4333 | 0.42 (0.28-0.65) | 0.29 (Not available) | HR 1.67 (0.61-4.59) |
PARTNER TRIALSΔ[5] Various | 7273 | Not available | 0.52 (0.43-0.69) | 1257 | Not available | 0.41 (0.23-0.72) | IRR 1.27 (0.70-2.32) HR 1.15 (0.58-2.29) |
Do you want to add Medilib to your home screen?